Artemether-lumefantrine

Novartis

Product vision
  • 3-day cure, artemisinin-based combination therapy (artemether-lumefantrine) for patients <5kg 
Therapeutic indication
  • First antimalarial for treatment of neonates and infants <5kg with uncomplicated P. falciparum infection
Dosing
  • Twice-daily for 3 days
Efficacy
  • Expected to be the same in adults and children >5kg population
Key features
  • New dispersible tablet with optimized artemether:lumefantrine ratio to provide appropriate exposure in the neonate and infant population
Status
  • Pharmacokinetic /pharmacodynamic (PK/PD) bridging registration study started in Africa
Next milestone
  • Pharmacokinetic/pharmacodynamic (PK/PD) bridging registration study completion
MMV Project Director
  • Dr Gonzalo Acuña